Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $2.0 million.

  • Arcutis Biotherapeutics' Non Operating Income fell 5133.91% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 4060.27%. This contributed to the annual value of $16.2 million for FY2024, which is 3722.21% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Non Operating Income stood at $2.0 million, which was down 5133.91% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Non Operating Income ranged from a high of $5.2 million in Q2 2024 and a low of -$1.7 million during Q1 2022
  • Moreover, its 5-year median value for Non Operating Income was $2.7 million (2023), whereas its average is $1.9 million.
  • Over the last 5 years, Arcutis Biotherapeutics' Non Operating Income had its largest YoY gain of 840000.0% in 2022, and its largest YoY loss of 404418.6% in 2022.
  • Over the past 5 years, Arcutis Biotherapeutics' Non Operating Income (Quarter) stood at -$40000.0 in 2021, then surged by 8400.0% to $3.3 million in 2022, then decreased by 19.52% to $2.7 million in 2023, then increased by 1.72% to $2.7 million in 2024, then dropped by 25.13% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.1 million for Q2 2025, and $2.7 million during Q1 2025.